From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment

Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)

Published: Jan. 6, 2025

Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents bibliometric analysis 416 articles retrieved from the WOSCC, Wan fang Data, CNKI VIP databases, spanning contributions 32 countries, 589 institutions 3,200 authors. identified "PD-L1," "PD-1" "pembrolizumab" as central foci, while "immune checkpoint inhibitors," "tumor immune microenvironment," "tertiary lymphoid structures" "durvalumab" emerged key areas interest. These findings emphasize pivotal role improving survival outcomes for CCA, they highlight significance tertiary structures within microenvironment promising target future research. offers strategic overview evolving landscape CCA immunotherapy, providing valuable insights to guide scientific endeavors domain.

Language: Английский

Comment on “Intrahepatic cholangiocarcinoma with FGFR alterations: A series of Chinese cases with an emphasis on their clinicopathologic and genetic features”

Digestive and Liver Disease, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский